Randomized clinical trial of a new dexamethasone delivery system (surodex) for treatment of post-cataract surgery inflammation11The authors have no financial interest in this or competing products or in Surodex or Oculex Pharmaceuticals, Inc.

Tan, Donald; Chee, Soon-Phaik; Lim, Liangzhong; Lim, Arthur

doi:10.1016/s0161-6420(99)90060-x

Cited by 108 publications

(25 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The research protocol used here was adopted from the methods of TAN et al (1999), which compared device efficacy to that of traditional treatment methods without the use of a placebo implant. We believe that the use of placebo (free of topical anti-inflammatory agents to treat postoperative uveitis) does not provide a fair comparison of the device to conventional treatments.…”

Section: Resultsmentioning

confidence: 99%

Effect of an intravitreal dexamethasone device on ocular inflammation after phacoemulsification in dogs

et al. 2016

View full text Add to dashboard Cite

This study examined the efficacy of an intravitreal dexamethasone-loaded device for the control of postoperative ocular inflammation in dogs following RESUMO O estudo examinou a eficácia de um dispositivo intravítreo de liberação de dexametasona para o controle da inflamação ocular em cães, após facoemulsificação. Um dispositivo de copolímero poli (ácido lático-co-glicólico) foi implantado via pars plana na câmera vítrea, imediatamente antes da facoemulsificação (grupo dispositivo [GD], n=20). Após a cirurgia, o grupo controle (GC) recebeu terapia esteroide, midriático e antibiótico. O mesmo protocolo de tratamento foi adotado no GD, exceto pelos esteroides. Todos os olhos foram examinados antes do procedimento e em diferentes tempos após a facoemulsificação. A ultrassonografia mostrou que o dispositivo diminuiu em tamanho, sendo observado, apenas, remanescentes aos 60 dias de pós-operatório (DPO). Sinais de uveíte foram observados em 35% do GD no DPO 7, entretanto, no DPO 14, 50% dos

show abstract

Section: Resultsmentioning

confidence: 99%

Effect of an intravitreal dexamethasone device on ocular inflammation after phacoemulsification in dogs

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Implants can deliver controlled and efficacious doses of steroids, decreasing the risk of systemic toxicity and ocular side effects. Surodex®, a dexamethasone anterior segment DDS (Oculex Pharmaceuticals Inc., USA), was developed to address the difficulties associated with topical corticosteroids to treat inflammation after cataract surgery and has proved to be effective [9, 10]. However, as the device is not sutured into place, adverse events like peripheral anterior synechiae and migration of the implant to the interface between the posterior convexity of the IOL and the posterior capsule may occur [16].…”

Section: Discussionmentioning

confidence: 99%

“…Thus, the topical route requires the use of highly concentrated repeated doses, which can lead to poor patient compliance and can cause several adverse effects, such as corneal toxicity and ocular discomfort [4]. Many alternatives to overcome the difficulties related to eyedrops have been developed, such as microemulsions [5], sub-Tenon injections [6], transscleral delivery [7], iontophoresis [8] and implants [9, 10, 11]. Our group developed a new intraocular lens (IOL) containing a biodegradable dexamethasone drug delivery system (DDS).…”

Section: Introductionmentioning

confidence: 99%

Pharmacokinetic and Toxicity Investigations of a New Intraocular Lens with a Dexamethasone Drug Delivery System: A Pilot Study

Siqueira¹,

Filho

Fialho

et al. 2006

Ophthalmologica

View full text Add to dashboard Cite

Aim: To investigate the short-term safety and pharmacokinetic behavior of a new intraocular lens containing a dexamethasone drug delivery system (IOL-DDS) in rabbit eyes. Methods: A modified polymethylmethacrylate IOL containing a biodegradable dexamethasone DDS was implanted into the posterior chamber of the right eyes of 9 New Zealand white rabbits. Serial slitlamp and indirect ophthalmoscopic examinations (including grading of intraocular inflammation) were performed. After 3, 6 and 9 days, the rabbits were euthanized and the globes were removed for histological examination and for determination of dexamethasone levels in the aqueous humor and in the vitreous. Analysis of dexamethasone concentrations was performed by ELISA. Results: Therapeutic concentrations of dexamethasone were detectable in the aqueous and vitreous of the study eyes throughout the 9-day period in all tested animals. The mean aqueous dexamethasone concentration (ng/ml, ±SD) was 1,015.42 (±43.05), 970.11 (±32.47) and 757.58 (±30.19) and the mean vitreous concentration (ng/ml, ±SD) was 399.82 (±38.05), 287.38 (±34.47) and 268.15 (±32.00) at 3, 6 and 9 days after the surgical procedure, respectively. No corneal or retinal histological changes were observed during the study period. Conclusion: The IOL-DDS is effective in delivering therapeutic concentrations of dexamethasone to the aqueous and vitreous, without acute damage to the cornea and retina. Further controlled studies in the same animal model are under way to determine the potential value of this lens in the prevention and treatment of inflammation following cataract surgery.

show abstract

“…An advantage of the IOL+DDS is that it combines cataract surgery and postoperative treatment in a single procedure. Another advantage is its release of low drug concentrations that are effective and have few side effects (77). Moreover, patient noncompliance as well as the need for a second surgery to remove the implant is eliminated.…”

Section: Biodegradable Devicesmentioning

confidence: 99%

Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

2009

View full text Add to dashboard Cite

Abstract. Recently, the use of triamcinolone acetonide (TA) injection has increased dramatically in treatment for several ocular diseases. Among them, macular diseases such as macular edema due to diabetic retinopathy, venous occlusive diseases, ocular inflammation and age-related macular degeneration (AMD) are very common vision threatening disorders and are great challenges to treat. In these types of chronic retinal diseases, repeated intraocular injections of TA are often required which increases the likelihood of complications. In order to achieve sustained-release, maintain therapeutic levels of TA over longer times and reduce frequency of intravitreal injections, researchers are investigating different implantable devices or injectable systems. However, as of yet, there is no sustained-release product for TA available on the commercial market. This review discusses and compares different sustained-release devices or injectable systems that are currently being developed.

show abstract

Randomized clinical trial of a new dexamethasone delivery system (surodex) for treatment of post-cataract surgery inflammation11The authors have no financial interest in this or competing products or in Surodex or Oculex Pharmaceuticals, Inc.

Cited by 108 publications

References 17 publications

Effect of an intravitreal dexamethasone device on ocular inflammation after phacoemulsification in dogs

Effect of an intravitreal dexamethasone device on ocular inflammation after phacoemulsification in dogs

Pharmacokinetic and Toxicity Investigations of a New Intraocular Lens with a Dexamethasone Drug Delivery System: A Pilot Study

Intraocular Sustained-Release Delivery Systems for Triamcinolone Acetonide

Contact Info

Product

Resources

About